Clinical Trial: A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naive Chronic Lymphocytic Leukemia

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07674810) titled 'A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naive Chronic Lymphocytic Leukemia' on June 26.

Brief Summary: The goal of this clinical research study is to learn if the combination of zanubrutinib, sonrotoclax, and obinutuzumab can help to control previously untreated CLL/SLL.

Study Start Date: Dec. 31, 2026

Study Type: INTERVENTIONAL

Condition: Chronic Lymphocytic Leukemia

Intervention: DRUG: Zanubrutinib

Given orally

DRUG: Obinutuzumab

Given orally

DRUG: Sonrotoclax

Given orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

D...